The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review

References

• Eccles M., Freemantle N., Mason J. North of England evidence based guidelines development project: methods of developing guidelines for efficient drug use in primary care. BMJ 1998; 316: 1232–5
   PubMed Web of Science ®Google Scholar
• Tugwell P., Shea B., Boers M., Brooks P., Simon L., Strand V., et al. Evidence‐based rheumatology, 1st edn. BMJ Books, London 2004
   Google Scholar
• Bucher H. C., Guyatt G. H., Griffith L. E., Walter S. D. The results of direct and indirect treatment comparisons in meta‐analysis of randomised controlled trials. J Clin Epidemiol 1997; 6: 683–91
   Google Scholar
• Lumley T. Network meta‐analysis for indirect treatment comparison. Stat Med 2002; 21: 2313–24
   PubMed Web of Science ®Google Scholar
• Lu G., Ades A. E. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004; 23: 3105–24
   PubMed Web of Science ®Google Scholar
• Lee D. M., Weinblatt M. E. Rheumatoid arthritis. Lancet 2001; 358: 903–11
   PubMed Web of Science ®Google Scholar
• Emery P. Treatment of rheumatoid arthritis. BMJ 2006; 332: 152–5
   PubMed Web of Science ®Google Scholar
• Blumenauer B., Judd M., Wells G., Burls A., Cranney A., Hochberg M., et al. Infliximab for the treatment of rheumatoid arthritis. Cochrane Database Syst Rev 2002, (3): CD003785
   Google Scholar
• Blumenauer B., Judd M., Cranney A., Burls A., Coyle D., Hochberg M., et al. Etanercept for the treatment of rheumatoid arthritis. Cochrane Database Syst Rev 2003, (4): CD004525
   Google Scholar
• Navarro‐Sarabia F., Ariza‐Ariza R., Hernandez‐Cruz B., Villanueva I. Adalimumab for treating rheumatoid arthritis. Cochrane Database Syst Rev 2005, (3): CD005113
   Google Scholar
• Furst D. E., Breedveld F. C., Kalden J. R., Smolen J. S., Burmester G. R., Bijlsma J. W. J., et al. Updated consensus statement on biological agents, specifically tumor necrosis factor α (TNF‐α) blocking agents and interleukin‐1 receptor antagonist (IL‐1ra), for the treatment of rheumatic diseases, 2005. Ann Rheum Dis 2005; 64: iv2–14
   PubMed Web of Science ®Google Scholar
• Walter S. D. Number needed to treat (NNT): estimation of a measure of clinical benefit. Stat Med 2001; 20: 3947–62
   PubMed Web of Science ®Google Scholar
• Osiri M., Suarez‐Almazor M. E., Wells G. A., Robinson V., Tugwell P. Number needed to treat (NNT): implication in rheumatology clinical practice. Ann Rheum Dis 2003; 62: 316–21
   PubMed Web of Science ®Google Scholar
• Altman D. G. Confidence intervals for the number needed to treat. BMJ 1998; 317: 1309–12
   PubMed Web of Science ®Google Scholar
• Song F., Altman D. G., Glenny A. M., Deeks J. J. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta‐analyses. BMJ 2003; 326: 472
   PubMed Web of Science ®Google Scholar
• Cates C. J. Simpson's paradox and calculation of number needed to treat from meta‐analysis. BMC Med Res Methodol 2002; 2: 1
   PubMedGoogle Scholar
• Altman D. G., Deeks J. J. Meta‐analysis, Simpson's paradox, and the number needed to treat. BMC Med Res Methodol 2002; 3, 2
   PubMedGoogle Scholar
• Nixon R. M., Bansback N., Brennan A. Using mixed treatment comparisons and meta‐regression to perform indirect comparisons to estimate efficacy of biologic treatments in rheumatoid arthritis. Stat Med 2007; 26: 1237–54
   PubMed Web of Science ®Google Scholar
• Hochberg M. C., Tracy J. K., Hawkins‐Holt M., Flores R. H. Comparison of the efficacy of the tumor necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis. Ann Rheum Dis 2003; 62(Suppl II): ii13–16
   Google Scholar
• Gartlehner G., Hansen R. A., Jonas B. L., Thieda P., Lohr K. N. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and meta‐analysis. J Rheumatol 2006; 33: 2398–407
   PubMed Web of Science ®Google Scholar
• Fahey T., Griffiths S., Peters T. J. Evidence‐based purchasing: understanding results of clinical trials and systematic reviews. BMJ 1995; 311: 1056–9
   PubMed Web of Science ®Google Scholar
• Kristensen L. E., Saxne T., Geborek P. The LUNDEX, a new index of drug efficacy in clinical practice: results of a five‐year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden. Arthritis Rheum 2006; 54: 600–6
   PubMed Web of Science ®Google Scholar
• Chung C. P., Thompson J. L., Koch G. G., Amara I., Strand V., Pincus T. Are American College of Rheumatology 50% response criteria superior to 20% criteria to distinguish active aggressive treatment in rheumatoid arthritis clinical trials reported since 1997? A meta‐analysis of discriminant capacities. Ann Rheum Dis 2006; 65: 1602–7
   PubMed Web of Science ®Google Scholar
• Felson D. T., Anderson J. J., Boers M., Bombardier C., Furst D., Goldsmith C., et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727–35
   PubMed Web of Science ®Google Scholar
• Altman D. G., Schulz K. F., Moher D., Egger M., Davidoff F., Elbourne D., et al. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 2001; 134: 663–94
   PubMed Web of Science ®Google Scholar
• Dr Chris Cates' EBM Web Site. www.nntonline.com Updated April 2006; accessed 20 April 2006.
   Google Scholar
• Bathon J. M., Martin R. W., Fleischmann R. M., Tesser J. R., Schiff M. H., Keystone E. C., et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343: 1586–93
   PubMed Web of Science ®Google Scholar
• Moreland L. W., Schiff M. H., Baumgartner S. W., Tindall E. A., Fleischmann R. M., Bulpitt K. J., et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999; 130: 478–86
   PubMed Web of Science ®Google Scholar
• Weinblatt M. E., Kremer J. M., Bankhurst A. D., Bulpitt K. J., Fleischmann R. M., Fox R. I., et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 253–9
   PubMed Web of Science ®Google Scholar
• Klareskog L., van der Heijde D., de Jager J. P., Gough A., Kalden J., Malaise M., et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double‐blind randomised controlled trial. Lancet 2004; 363: 675–81
   PubMed Web of Science ®Google Scholar
• Furst D. E., Schiff M. H., Fleichmann R. M., Strand V., Birbara C. A., Compagnone D., et al. Adalimumab, a fully human anti‐tumor necrosis factor alpha monoclonal antibody, and concomitant standard antirheumatic therapy for treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003; 30: 2563–71
   PubMed Web of Science ®Google Scholar
• Keystone E. C., Kavanaugh A. F., Sharp J. T., Tannenbaum H., Hua Y., Teoh L. S., et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti‐tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy. A randomized, placebo‐controlled, 52‐week trial. Arthritis Rheum 2004; 50: 1400–11
   PubMed Web of Science ®Google Scholar
• Rau R., van Riel P. L. C. M., van de Putte L. B. A., Kruger K., Schattenkirchner M., Allaart C. F., et al. Rapid alleviation of signs and symptoms of rheumatoid arthritis with intravenous or subcutanous administration of adalimumab in combination with methotrexate. Scand J Rheumatol 2004; 33: 145–53
   PubMed Web of Science ®Google Scholar
• Van de Putte L. B. A., Rau R., Breedveld F. C., Kalden J. R., Malaise M. G., van Riel P. L. C. M., et al. Efficacy and safety of the fully human anti‐tumor necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. Ann Rheum Dis 2003; 62: 1168–77
   PubMed Web of Science ®Google Scholar
• Weinblatt M. E., Keystone E. C., Furst D. E., Moreland L. W., Weisman M. H., Birbara C. A., et al. Adalimumab, a fully human anti‐tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003; 35–45, 48
   PubMedGoogle Scholar
• Lipsky P. E., van der Heijde D. M., St Clair E. W., Furst D. E., Breedveld F. C., Kalden J. R., et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti‐Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000; 343: 1594–602
   PubMed Web of Science ®Google Scholar
• Maini R. N., Breedveld F. C., Kalden J. R., Smolen J. S., Davis D., Macfarlane J. D., et al. Therapeutic efficacy of multiple intravenous infusions of anti‐tumor necrosis factor alpha monoclonal antibody combined with low‐dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1552–63
   PubMed Web of Science ®Google Scholar
• Maini R., St Clair E. W., Breedveld F., Furst D., Kalden J., Weisman M., et al. Infliximab (chimeric anti‐tumor necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. Lancet 1999; 354: 1932–9
   PubMed Web of Science ®Google Scholar
• Chen Y. F., Jobanputra P., Barton P., Jowett S., Bryan S., Clark W. W., et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost‐effectiveness. Health Technol Assess 2006; 10: 1–248
   Web of Science ®Google Scholar
• Bingham C. O., Barnes J., Yuan Y., Beresniak A. Number needed to treat comparison of biologic agents in rheumatoid arthritis. Arthritis Rheum 2006; 54(Suppl): Abstract 762
   Google Scholar
• Kristensen L. E., Saxne T., Nilsson J. A., Geborek P. Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six‐year observational study in southern Sweden. Arthritis Res Ther 2006; 8: R174
   PubMed Web of Science ®Google Scholar